Disproportionate Effects of Legal Restrictions on Medication Abortion
In a new commentary in Contraception, the authors argue that permanently lifting the FDA’s Risk Evaluation and Mitigation Strategy (REMS) for mifepristone in its entirety would expand access to early abortion and miscarriage care.